A carregar...
Pulse afatinib for ERBB2 exon 20 insertion mutated lung adenocarcinomas
INTRODUCTION: Genomic aberrations involving erb-b2 receptor tyrosine kinase 2 (ERBB2) are driver oncogenes in ∼2% of lung adenocarcinomas. However, the use of daily dosing of ERBB2 tyrosine kinase inhibitors (TKIs) - including afatinib - has been fraught by plasma concentrations that barely achieve...
Na minha lista:
| Publicado no: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4877224/ https://ncbi.nlm.nih.gov/pubmed/26964772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.02.016 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|